

HEMOGLOBINOPATHIES

PROF. DENIZ ASLAN, MD
GAZI UNIVERSITY, FACULTY OF MEDICINE,
SECTION OF PEDIATRIC HEMATOLOGY,
ANKARA-2024

HEMOGLOBINOPATHY

(DISORDERS OF HEMOGLOBIN)

1-REDUCED SYNTHESIS OF NORMAL HEMOGLOBIN

Thalassemias

2-SYNTHESIS OF AN ABNORMAL HEMOGLOBIN

Hb S (Sickle Cell Anemia)

Hb C

Hb D

Hb E

Methemoglobin

THALASEMIAS

A heterogeneous group of disorders

The most frequent of the inherited diseases in the world


Monogenic disease

There is an inherited defect in rate of synthesis of one or more globin chains


- -Alpha
- -Beta
- -Deltabeta

Common in thalassemia belt countries


THALASSEMIA BELT




PATHOPHYSIOLOGY - Hemoglobin



PATHOPHYSIOLOGY



PATHOGENESIS



BETA THALASSEMIA


Beta-globin gene affected

2 genes


Located on chromosome 11

Point mutations


Population specific mutations



Beta Thalassemia Mutations



Beta Thalassaemia Mutations




BETA THALASSEMIA

2 GENES - **Thalassemia Major**


- Homozygous
- Compound heterozygous (thalassemia intermedia)

1 GENE - **Thalassemia Minor**

- Heterozygous



PATHOGENESIS



Facial appearance



© Elsevier, Nussbaum et al: Thompson and Thompson's Genetics in Medicine 7e - www.studentconsult.com

General view



Skull X-Ray



LABORATORY

COMPLETE BLOOD COUNT

- Severe anemia (Hb 2-3 gr/dl)
- Peripheral smear-anisopoikilocytosis

BONE MARROW

- Erythroid hyperplasia

HEMOGLOBIN ELECTROPHORESIS

- Hb F ↑ (10-90%)
- Hb A absent
- Hb A2 N, ↓, ↑


GLOBIN CHAIN ANALYSIS

- Alfa/beta ratio abnormal (↑)

MUTATION ANALYSIS

- Point mutations

Peripheral Smear



MANAGEMENT

1- Blood Transfusion

2- Iron Chelation

3- Splenectomy

4- Stem Cell Transplantation

Endocrine replacement

Immunisation

TRANSFUSION

Once a month


Red cell suspension
10 ml/kg

Hb before – after transfusion
(9 – 12 gr/dl)



Iron Overload (Hemochromatosis)

Demir yüklenmesine bağlı organ hasarı



Klinik

- Pituiter → Büyüme bozukluğu
- Kalp → Kardiyomyopati, kalp yetmezliği
- Karaciğer → Siroz
- Pankreas → Diabetes Mellitus
- Gonadlar → hipogonadizm, infertilite

Courtesy of Dr. M. D. Cappellini.

Evaluation of Iron Overload

1-Serum ferritin level*

2-Marrow iron assesement (marrow aspiration)

3-Hepatic iron assesement (liver biopsy)

4-Liver / Marrow CT/MRI (T2*)

IRON CHELATION

Desferal (DFO)

- Subcutaneous (SC) infusion
- 20-40 mg/kg
- Every day of a week
- Nightly infusion for 8-12 hours
- With Vitamin C (ascorbic acid)

Weak compliance!

Expensive!

Desferal Pump



Other Chelation Agents

Ferriprox (deferiprone)

Exjade (deferasirox)

Fuarte

Defroni

Side effects (Agranulocytosis, neutropenia, GI symptoms)

EXJADE

Per oral (PO)
After 2 years of age
20 mg/kg/day



Exjade-Tabletten

125 mg



250 mg



500 mg



Tabletten nicht in tatsächlicher Grösse abgebildet

SPLENECTOMY

When blood requirement is increased

- 200 ml/kg/year ↑

After the age of 5

Immunisation



BTM child, X15 spleen

STEM CELL TRANSPLANTATION

Curative

80 % success rate

- HLA-matched donor
 - Only 10% of patients!
- Before 16-year of age
- Hepatomegaly absent

ENDOCRINE THERAPY

Replacement of deficient hormone

Diabetes therapy

IMMUNISATION

Hepatit B



BETA THALASSEMIA INTERMEDIA


Compound heterozygosity

Clinical phenotype moderate

No need for regular transfusion

Iron overload may develop

- Increased intestinal absorption



BETA THALASSEMIA MINOR


No symptoms

Microcytosis on CBC (MCV 80 fl ↓)

Hemoglobin electrophoresis Hb A2 ↑ (%3.5 and above)



Genetic Counseling



U.S. National Library of Medicine

BETA THALASEMIA PRENATAL DIAGNOSIS

1-CHORDOSYNTHESIS

Cord blood (globin chain synthesis)

Delayed diagnosis

2-CHORIONIC VILLUS SAMPLING (CVS)

Amniosynthesis (DNA analysis)

Early diagnosis

Pre-Implantation Genetic Diagnosis (PGD)

Looking for the genetic alterations that affect a particular gene, one can avoid the transmission of diseases such as cystic fibrosis, thalassemia or muscular dystrophy, among others.




Chromosomal alterations affect either the number or the structure of chromosomes. This technique allows their detection as well as the detection of other alterations, such as, Turner and Down syndromes.



A Genetic study


Following the in vitro fertilization and before transfer into the uterus, a study of the genetic material of the embryo is carried out to detect possible genetic defects.



It is performed when the embryos are between 6 and 8 cells, usually on day 3 of development.

B Embryo Biopsy

A biopsy is performed on each of the embryo to discard those with concrete congenital flaws.



C Embryo transfer

From 1 to 3 healthy embryos are transferred.



The embryos that are not transferred can be frozen.

GENE THERAPY

Experimental level...

ALPHA THALASEMIA

Alpha globin chain synthesis disturbed

Alpha globin gene **deletion**

4 genes

Chromosome 16

Clinical phenotype variability



GENOTYPE-CLINICAL PHENOTYPE

α -thalassemia(genetic)

NO. OF GENES PRESENT	GENOTYPE	CLINICAL CLASSIFICATION
4 genes	$\alpha\alpha/\alpha\alpha$	Normal
3 genes	$\alpha\alpha/-\alpha$	Silent carrier
2 genes	$-\alpha/-\alpha$ or $\alpha\alpha/-$ $-$	α thalassemia trait
1 gene	$-\alpha/-$ $-$	Hb H Ds
0 genes	$- -/-$ $-$	Hb Barts / Hydrops fetalis

HYDROPS FETALIS 4 alpha globin genes deleted



courtesy: Dr. Indrajit Rana

REFERENCES

Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012 Jan 28;379(9813):373-83.

Higgs DR. The molecular basis of α -thalassemia. Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a011718.

Serjeant GR, Serjeant BE, Fraser RA, et al. Hb S- β -thalassemia: molecular, hematological and clinical comparisons. Hemoglobin. 2011;35(1):1-12.

Higgs DR, Gibbons RJ. The molecular basis of α -thalassemia: a model for understanding human molecular genetics. Hematol Oncol Clin North Am. 2010 Dec;24(6):1033-54.

Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010 May 28;5:13.

Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci. 2009 :1154-62.



Higgs DR. Gene regulation in hematopoiesis: new lessons from thalassemia. Hematology Am Soc Hematol Educ Program. 2004:1-13.

SICKLE CELL ANEMIA (SCA)

Normal RBC



HbSS RBC



Hb S synthesis

Result of the substitution of valine for glutamic acid at position 6 in the beta chain

Sensitive to hypoxia

Strong tendency to aggregate in a highly ordered fashion, resulting in multiple microtubules arranged in helical form

Deforms red cell into a variety of rigid shapes, including the classical sickle shape


Blood viscosity $\uparrow$, vascular stasis, tissue damage:

Pain


When a cell sickles and unsickles repeatedly, irreversible membrane damage occurs, cell is destroyed:

Anemia

Sickling process



SCA (peripheral smear) - sickle shape



SCA - Complications

Acute chest syndrome

Organ failures

- Kidneys (medullar hypoxia, papillary necrosis, hypostenuria)

Cholelithiasis

Hand-Foot syndrome

Pulmonary hypertension

Stroke and eye complications

Priapism

Autosplenectomy

SCA - Symptoms



SCA - Hand-Foot Syndrome



SCA - CRISES

Vaso-occlusive or painful crises

Sequestration crises

Aplastic crises

Hemolytic crises (?)

SCA – Precipitating Factors

Hypoxia

Dehydration

Infection

Cold

Altitude

Exercise

SCA - WHEN SUSPECTED?

Unexplained pain and swelling (esp. in hands and feet)

Pneumonia

Menengitidis

Sepsis

Neurological findings

Splenomegaly

Anemia

SCA - DIAGNOSIS

Sickling test (screening test)

Peripheral smear

Hemoglobin electrophoresis

Mutation analysis

SCA - MANAGEMENT

Prophylaxis

Pain management

Reducing abnormal hemoglobin (Hb S)

Stem cell transplantation

PROPHYLAXIS


- To avoid the precipitating factors
 - Dehydration
 - Hypoxia
 - Infection
 - Cold
 - Altitude
 - Exercise

ANALGESIA Drug Addiction!

Mild - Acetaminofen, NSAID+Opioid

Moderate - Sedative, anxiolytics

Severe - Morphin, Meperidine



REDUCING ABNORMAL HB S (30% ↓)

Blood transfusion

Exchange transfusion

Plasmapheresis (red cell exchange apheresis)

Hidroxyurea

Plasmapheresis



Hidroxyurea

Hb F↑

HbS ↓

Tissue oxygenisation↑

Inflammation ↓

- Crises ↓



STEM CELL TRANSPLANTATION

Severe cases

HLA matched donor 20%

Success rate ~100%

Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks.

[Rafii H](#)¹, [Bernaudin F](#)², [Rouard H](#)³, [Vanneaux V](#)⁴, [Ruggeri A](#)⁵, [Cavazzana M](#)⁶, [Gauthereau V](#)⁷, [Stanislas A](#)⁸, [Benkerrou M](#)⁹, [De Montalembert M](#)¹⁰, [Ferry C](#)¹¹, [Giot R](#)¹², [Arnaud C](#)¹³, [Kamdem A](#)¹⁴, [Gour J](#)¹⁵, [Touboul C](#)¹⁶, [Cras A](#)¹⁷, [Kuentz M](#)¹⁸, [Rieux C](#)¹⁹, [Volt F](#)²⁰, [Cappelli B](#)²¹, [Maio KT](#)²², [Paviglianiti A](#)²⁰, [Kenzey C](#)²⁰, [Larghero J](#)²³, [Gluckman E](#)²⁴.

 **Author information**

[Hum Gene Ther Clin Dev](#). 2017 Apr 17. doi: 10.1089/humc.2017.029. [Epub ahead of print]

Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.

[Uchida N](#)¹, [Fujita A](#)¹, [Hsieh MM](#)¹, [Bonifacino AC](#)², [Krouse AE](#)², [Metzger ME](#)², [Donahue RE](#)², [Tisdale JF](#)¹.

 **Author information**

SICKLE CELL TRAIT

Hb S 30%

No crisis in normal conditions

- Only severe hypoxia/infection can precipitate crisis

Normally shaped red cells on smear

No anemia

OTHER ABNORMAL HEMOGLOBINS Hb variants

Hb C *Beta 6 Glu>Lys*

Hb D *Beta 121 Glu<Gln*

Hb E *Beta 26 Glu>Lys*

S-C

S-D

S-E

SUPPORT GROUPS



Northern California
Comprehensive Thalassemia Center



REFERENCES

Sickle Hemoglobin. Chap L12, p. L43 in Williams Hematology. 5/e 1995.

Oshrine B, Talano JA. Curative treatment for severe sickle cell disease: allogeneic transplantation. Clin Adv Hematol Oncol. 2015 Apr;13(4):249-56.

Connes P, Alexy T, Detterich J, et al. The role of blood rheology in sickle cell disease. Blood Rev. 2015 Aug 28. pii: S0268-960X(15)00066-1.

Pule GD, Mowla S, Novitzky N, et al. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol. 2015 Oct;8(5):669-79.

Alavi A, Kirsner RS. Hemoglobinopathies and Leg Ulcers. Int J Low Extrem Wounds. 2015 Aug 20. pii: 1534734615600069.

Voskou S, Aslan M, Fanis P, et al. Oxidative stress in β -thalassaemia and sickle cell disease. Redox Biol. 2015 Aug 1;6:226-239.

Bhatia M, Sheth S. Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med. 2015 Jul 10;6:229-38.

Archer N, Galacteros F, Brugnara C. 2015 Clinical Trials Update in Sickle Cell Anemia. Am J Hematol. 2015 Jul 15.